Atopic dermatitis treatment in Kochi,
SCORAD-graded, barrier-repair first.

STAND-AD is the IADVL Special Interest Group of Pediatric Dermatology modified Delphi consensus published in IJDVL, the Indian standardised diagnosis and management protocol for atopic dermatitis. Key Indian-context elements: cyclosporine 3-5 mg/kg/day OR oral prednisolone as first-line systemic for moderate-severe AD (rather than dupilumab, which is highly effective but cost-restricted in India); emollients + topical steroid + topical calcineurin inhibitor (tacrolimus 0.1% for face/folds to avoid long-term steroid atrophy) as topical foundation; methotrexate / azathioprine for maintenance.

Yes, dupilumab (IL-4/13 monoclonal antibody, 600 mg loading + 300 mg every 2 weeks subcutaneous) is available in India and highly effective for moderate-severe atopic dermatitis. The IADVL STAND-AD panel explicitly recommends it where accessible. The dominant barrier is cost: annual programme is approximately ₹2.5-4 lakh. DermaVue Kochi counsels eligible patients on dupilumab where conventional cyclosporine / methotrexate has failed or where the patient has budget capacity for biologic therapy.

JAK (Janus kinase) inhibitors are oral targeted therapies that block specific inflammatory signalling pathways involved in atopic dermatitis. Three JAK inhibitors are approved for AD globally: abrocitinib (JAK1-selective), upadacitinib (JAK1-selective), baricitinib (JAK1/2). Highly effective in head-to-head trials versus dupilumab and conventional therapy. Indian availability is expanding but cost remains a barrier, monthly cost ₹15,000-30,000 for abrocitinib. Pre-treatment screen (TB, hepatitis, HIV, LFTs, baseline bloods) is required.

Atopic dermatitis is a chronic relapsing-remitting condition with no permanent cure, flares are part of the disease model, not treatment failure. Common Indian-context triggers: food allergens (egg, milk, peanut, soy, wheat, household-specific patterns), dust mites (very high RH areas including Kerala have heavy dust mite burden), contact allergens (fragrance in baby products, fabric softeners), staphylococcal colonisation (chronic plaque AD is often colonised), and stress (psychoneuroimmunology). DermaVue's structured trigger workup + emollient maintenance reduces flare frequency meaningfully, but does not eliminate the underlying disease.

Topical corticosteroids are safe when used correctly: class-matched to body region (low-potency for face / folds / paediatric; mid-potency for body; high-potency only short courses for thick plaques), pulsed (not continuous), and supplemented with steroid-sparing alternatives. Long-term unmonitored topical steroid use risks skin atrophy, telangiectasia, perioral dermatitis, and steroid-rebound. The IADVL approach uses topical calcineurin inhibitors (tacrolimus 0.1% or pimecrolimus 1%) for face / folds maintenance to avoid long-term steroid atrophy in these high-risk anatomical areas.

Atopic dermatitis is fundamentally a skin barrier defect (often genetic, filaggrin mutations) with secondary inflammatory response. Restoring the barrier with regular emollient application (2-4 times daily, ceramide / colloidal oatmeal / petrolatum-based, fragrance-free) reduces transepidermal water loss, reduces allergen + microbial penetration, and reduces flare frequency by 30-50% in mild-moderate AD. Emollients are the non-negotiable foundation of every AD treatment plan, topical steroids and systemic agents address the inflammation; emollients address the underlying cause.

Yes, adult-onset AD accounts for 25-30% of all atopic dermatitis cases in dermatology practice. Presentation differs from childhood AD: more chronic plaque pattern (hands, neck, face, eyelids), more lichenification from chronic scratching, often with concomitant contact dermatitis or stress as trigger. Treatment protocol is similar to childhood AD: SCORAD scoring + trigger workup + emollients + topical therapy + systemic for moderate-severe.

₹300 consultation + SCORAD scoring. Emollient 3-month supply ₹1,500-4,500. Topical regimen (steroid + tacrolimus) ₹150-1,500/month. Cyclosporine 3-month course ₹7,500-18,000. Methotrexate 3-month course ₹450-1,500. Dupilumab annual programme ₹2.5-4 lakh (cost-restricted). Abrocitinib oral JAK monthly ₹15,000-30,000. Total cost depends on severity and chosen therapy line · DermaVue provides written annual cost projection before commitment to systemic or biologic therapy.

Many pediatric AD cases improve with age, approximately 50-60% of children with AD see substantial improvement by adolescence, though some persist into adulthood. Adult-onset AD is typically chronic. Even patients who experience remission may have flares triggered by stress, pregnancy, environmental change. The genetic predisposition (atopic march, AD + asthma + allergic rhinitis often co-occur) does not change with age. Long-term emollient maintenance + trigger awareness is the lifelong strategy.

Selectively, food allergy is a documented trigger for AD in some patients (commonly egg, milk, peanut, soy, wheat in young children), and identified food triggers should be avoided. BUT random food elimination diets without confirmed allergy testing can cause nutritional deficiency and rarely improves AD. DermaVue's approach: structured food allergy workup (skin prick test, specific IgE) for children with moderate-severe AD + suspected food trigger; targeted avoidance of confirmed triggers only; not elimination diets based on speculation.